In a phase I clinical trial, among seven patients with metastatic melanoma who were treated with stereotactic body radiation therapy followed by interleukin-2 (IL-2), 71% achieved a complete or partial response compared to 16% that was previously reported in association with IL-2 monotherapy (22, 23). The gene discussed is IL2; the disease is metastatic melanoma.